THALES
16.3.2020 07:02:07 CET | Business Wire | Press release
Thales and Telstra, Australia’s leading telecommunications company are working with Microsoft and Arduino to pave the way for scalable security for connected IoT devices, by implementing a solution that enables trusted and secure end-to-end communication between device and cloud.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200315005014/en/
The solution enables instant and standardised mutual authentication between a device and a cloud platform via cellular networks, while fully-complying with GSMA IoT SAFE security specifications.
Within the IoT ecosystem, billions of devices collect, process and send data to the cloud, where a range of different IoT services are executed. To enable security, the IoT cloud service must have absolute trust in data received from connected devices. Equally, devices need to trust the cloud. This is only possible if the device and server are mutually authenticated. However, the IoT devices market is so fragmented - with a patchwork of different operating systems and chips being utilised - that security services scalability and duplication are very limited.
That’s why Thales, Telstra, Microsoft1 and Arduino2 decided to team up to work on a solution that addresses the challenge of securely and efficiently connecting IoT devices to clouds in the most simplified way and through cellular networks. The level of trust required is enabled by a sophisticated ‘security-by-design ’ approach for any IoT devices based on field-proven and standardised SIM or eSIM technology.
As a result, as soon as an IoT device is switched on, any SIM or eSIM featuring Thales’s IoT SAFE application is automatically and securely provisioned. Once the IoT device gets a proper Digital Certificate created and stored in the SIM/eSIM, then a trusted communication between the device and the server is permitted, in full respect of data integrity and confidentiality.
“The key role of GSMA IoT Safe specifications is to deliver scalable and future-proof IoT security for cellular networks. Being able to in future offer standardised easy to implement IoT security to our customers as part of our existing IoT connectivity service, is a huge leap forward in terms of IoT security for all use cases, including smart energy, automotive, health, and home solutions. We look forward to trialling this reference design with our IoT solutions,” said Gerhard Loots, Global IoT Solutions Executive at Telstra .
"As an active contributor of the GSMA specifications, and world leader in over-the-air platform solutions for credential life-cycle management, Thales is a key partner to address the challenge of scalable IoT security. With this hassle-free approach we support a sustainable and scalable trusted ecosystem from which all key stakeholders such as mobile network operators, device manufacturers, and IoT industries can benefit,” said Emmanuel Unguran, SVP Mobile and Connectivity Solutions at Thales .
“The collaborative effort between these international organizations demonstrates the importance of simplifying IoT security without compromise. By bringing together each IoT technology layer; device, software, network and cloud, we can deliver a more streamlined approach to IoT security. This allows customers and partners to focus on creating business value from their solutions while ensuring their IoT deployments remain secure,” said Tony Shakib, General Manager, Azure IoT Business Acceleration at Microsoft Corp.
"We are very pleased to be part of the dream team composed by Thales, Telstra and Microsoft" said Fabio Violante, CEO of Arduino. "The development of this tool was a teamwork and a proof that Arduino is a great partner to create solid, reliable and easy to integrate hardware and software IoT solutions."
About Thales
Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 80,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a pro forma basis including Gemalto over 12 months).
Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments.
PLEASE VISIT
Thales Group
Digital Security
Download HD photos
1 Microsoft integrated the IoT SAFE solution with their Azure IoT Hub and also provided Azure Stream Analytics, Cosmos DB and Power BI services to quickly enable the development of an example end-to-end IoT application.
2 Arduino developed a library (under an open-source licence) which implements the security mechanism of the GSMA IoT Safe standard on their MKR NB 1500 boards and provides a valid alternative to the usage of the CryptoChip already present on the Arduino board. The project has been a great example of collaboration with companies operating in various IoT sectors, on which Arduino focuses for professional and industrial applications through the brand new Arduino Pro division.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200315005014/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
